Skip to content
Screener

PTC Therapeutics PTCT Liability Sale Of Future Royalties Current

Liability Sale Of Future Royalties Current at other companies

Mannkind logo
MannkindMNKD
$133.55M-2.7%
Mannkind logo
MannkindMNKD
$133.55M-2.7%
Mannkind logo
MannkindMNKD
$14.29M+7.1%
Mannkind logo
MannkindMNKD
$14.29M+7.1%
Regenxbio logo
RegenxbioRGNX
$42.56M+10.2%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$100M0.0%

Other financials

Income statement

See full
Revenue$272.6M-76.8%
Operating income$45.0M-95.4%
Net income-$2.8M-100%
EPS (diluted)-$0.03-100%

Balance sheet

See full
Cash & equivalents$834.0M-43.7%
Total debt$395.1M+0.1%
Total equity-$180.5M+2.9%
Total assets$2.9B+8.0%

Cash flow

See full
Operating cash flow-$59.0M-107%
CapEx$1.2M-30.6%
Free cash flow-$60.2M-107%

Valuation

See full
Market cap$5.91B+45.3%
Enterprise value$5.47B+58.8%
P/E7.3×
P/S7.2×+4.8×

Profitability

See full
Gross margin96%
Operating margin1.6%-38.7pp
Net margin42.3%+27.4pp
FCF margin39.1%+32.8pp

Returns & leverage

See full
Return on equity-216.7%
Debt / equity372.3×
Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept ptct:LiabilitySaleOfFutureRoyaltiesCurrent.

The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:32 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001070081-26-000012
Line itemMarch 31, 2026December 31, 2025
Deferred revenue4982,040
Operating lease liabilities- current12,07812,484
Finance lease liabilities- current6,0003,000
Liability for sale of future royalties- current305,041283,000
Total current liabilities923,604968,427
Operating lease liabilities- noncurrent90,07293,583
Finance lease liabilities- noncurrent3,000
Liability for sale of future royalties- noncurrent2,022,1892,025,366

Item 1. Financial Statements (unaudited)

FAQ

What is PTC Therapeutics's liability sale of future royalties current?
PTC Therapeutics (PTCT) reported liability sale of future royalties current of $305.04M in Q1 2026.
How has PTC Therapeutics's liability sale of future royalties current changed year-over-year?
PTC Therapeutics's liability sale of future royalties current increased by 22.9% year-over-year, from $248.24M to $305.04M.
What is the long-term trend for PTC Therapeutics's liability sale of future royalties current?
Over 5 years (2020 to 2025), PTC Therapeutics's liability sale of future royalties current has grown at a 68.2% compound annual growth rate (CAGR), from $21.02M to $283M.
What does liability sale of future royalties current mean?
This represents the portion of obligations arising from the monetization of future royalty streams that is due within the next twelve months. It reflects a financing strategy where the company receives upfront capital in exchange for a portion of future revenue generated by specific products. Investors track this to understand the impact of royalty-based financing on short-term cash flow and future revenue retention.

Ask your AI about PTC Therapeutics's liability sale of future royalties current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude